2024 IMS Translational Research Award

Eligibility

Eligibility: Applicant must be a faculty member or a scientist with an MD, and/or PhD, who is established as a researcher. Applicants with research experience outside of the field of plasma cell malignancies, who wishes now to apply their knowledge to developing translational research efforts focused on myeloma are encouraged. Women and underrepresented minorities are particularly encouraged to apply.  The PI or Co-I should be an IMS member. The applicant should agree to acknowledge IMS and the Paula and Rodger Riney Foundation as the funding source in any publication or presentation resulting from this funding. The applicants should provide a progress report at 6 months and at the end of the funding year and respond to periodic surveys for IMS.

Previous awardees will be eligible to reapply for an additional year, if adequate progress is demonstrated, and a need for additional resources is clearly defined to reach the translational potential.

Summary

The International Myeloma Society and Paula and Rodger Riney Foundation are proud to announce the fourth annual “IMS Translational Research Award,” funding grants focused on translational research in the field of plasma cell dyscrasias.

Goal: To foster and support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of plasma cell disorder. Although focused on finding a cure for multiple myeloma, the areas of research for this program are broad. This award will also encourage interaction between institutions to enhance collaborative research.

Research areas: Translational research projects in all areas of plasma-cell dyscrasia are eligible for this proposal. The Translational Research is defined in its broadest sense to include molecular assays, imaging techniques, drugs, biological agents, and/or other methodologies applicable to the treatment of myeloma. The translational research projects may involve the use of any cellular, molecular, structural, biochemical, and/or genetic experimental approaches. By this definition, projects are permitted to move not only in the forward direction, toward clinical trials and studies in areas of prevention, early detection, treatment, and development of biomarkers, but also in the reverse direction, using human biospecimens, often from clinical trials, to study new phenomena, or to develop new targets and treatments based on results from human studies. The project must be focused on translational research that meets the definition provided above and results in clinical translation. Project must be dedicated to capitalizing on research opportunities that have the potential to change the current paradigm in the management of myeloma.

Overhead

8% of direct costs.

Application deadlines

RSO detailed review deadline

RSO final internal review deadline

Program application deadline

NOTE: Consult your Faculty Associate Dean (Research) (ADR) regarding Faculty-specific deadlines and submission processes.

Principal Investigators: Complete a Research Management System (RMS) record, including a copy of your complete application, and submit this for approvals in RMS.

Approvals: The University of Calgary requires that all funding applications be approved prior to submission. Approval requires signatures via RMS in the following order:

• Principal Investigator
• Department Head
• Faculty ADR/Dean
• Research Services (on behalf of the Vice-President Research)

Read the Meaning of Grant Signatures policy to understand what your approval means. Please see the agency guidelines for details about which signatures are required on your application, as it may differ from internal requirements.

Late submissions: Late submissions will only be accepted in cases of medical or family emergencies, or other exceptional circumstances. If you submit your RMS record to Research Services after the internal deadline has passed, you must secure additional approvals. Please read: Late Applications Process.

Additional Resources

Application Portal